Risk Of Developing Liver Cancer After HCV Treatment

Monday, January 31, 2011

Hepatitis; List Of Clinical Trials Updated Jan 31 2011

Hepatitis Clinical Trials, Diagnosis, and Treatment
Thank you for your interest in clinical trials for Hepatitis.

Go to Clinical connection and enter your zip code to find the locations closest to you.
http://www.clinicalconnection.com/

Updated;Jan 31 2011

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-19139
Conditions: HCV InfectionLocation: Philadelphia, PA

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-20010
Conditions: HCV InfectionLocation: Washington, DC

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-32720
Conditions: HCV InfectionLocation: Deland, FL

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-32809
Conditions: HCV InfectionLocation: Orlando, FL

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-33169
Conditions: HCV InfectionLocation: Miami, FL

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-63104
Conditions: HCV InfectionLocation: St. Louis, MO

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-77030
Conditions: HCV InfectionLocation: Houston, TX

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-78215
Conditions: HCV InfectionLocation: San Antonio, TX

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-90630
Conditions: HCV InfectionLocation: Cypress, CA

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-91950
Conditions: HCV InfectionLocation: National City, CA

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-92801
Conditions: HCV InfectionLocation: Anaheim, CA

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-97239
Conditions: HCV InfectionLocation: Portland, OR

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-98418
Conditions: HCV InfectionLocation: Tacoma, WA

A Network & Dyad HIV Prevention Intervention for IDU's - 1 - NCT00218335-21231
Conditions: HIV - HepatitisLocation: Baltimore, MD

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-02114
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Boston, MA

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-07102
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Newark, NJ

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-10021
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: New York, NY

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-14642
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Rochester, NY

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-21093
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Lutherville, MD

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-23298
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Richmond, VA

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-34209
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Brandenton, FL

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-45267
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Cincinnati, OH

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-92103
Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: San Diego, CA

A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B - NCT00753467-91105
Conditions: Hepatitis BLocation: Pasadena, CA

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02114
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Boston, MA

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02115
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Boston, MA

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02903
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Providence, RI

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-06106
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Hartford, CT

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-10029
Conditions: Chronic Hepatitis B Virus, PediatricLocation: New York, NY

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-19104
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Philadelphia, PA

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-20010
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Washington, DC

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-21287
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Baltimore, MD

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-22031
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Fairfax, VA

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-28203
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Charlotte, NC

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-30322
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Atlanta, GA

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-32610
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Gainesville, FL

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-46202
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Inidanapolis, IN

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-77030
Conditions: Chronic Hepatitis B Virus, PediatricLocation: Houston, TX

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-94143
Conditions: Chronic Hepatitis B Virus, PediatricLocation: San Francisco, CA

A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C - NCT01250743-66160
Conditions: Hepatitis CLocation: Kansas City, KS

A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection - NCT01091077-02114
Conditions: Hepatitis C Virus - HCV Infection - Chronic HCV - Hepatitis CLocation: Boston, MA

A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation - NCT01074203-55905
Conditions: Hepatitis C RecurrenceLocation: Rochester, MN

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-10016
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: New York, NY

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-10021
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: New York, NY

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-19141
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Philadelphia, PA

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-21287
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Baltimore, MD

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-23249
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Richmond, VA

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-27599
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Chapel Hill, NC

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-27705
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Durham, NC

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32803
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Orlando, FL

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32809
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Orlando, FL

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-33136
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Miami, FL

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-46202
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Indianapolis, IN

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-48202
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Detroit, MI

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-53792
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Madison, WI

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-55114
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: St. Paul, MN

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-60611
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Chicago, IL

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-60612
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Chicago, IL

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-63104
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: St. Louis, MO

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70112
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: New Orleans, LA

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70808
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Baton Rouge, LA

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-75203A
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Dallas, TX
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-75203B
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Dallas, TX
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-77030
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Houston, TX

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-78215
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: San Antonio, TX

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-80045
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Aurora, CO

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-84132
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Salt Lake City, UT

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-85054
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Phoenix, AZ

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-90048
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Los Angeles, CA

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92037
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: La Jolla, CA

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92801
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Anaheim, CA

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-98101
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Seattle, WA

A Randomized Trial of Vaccine Adherence in Young Injection Drug Users - 1 - NCT00244374-94143Conditions: Adherence - Community Outreach - HIV Risk Behaviors - Hepatitis A Vaccines - Hepatitis B Vaccines - Hepatitis C - Needle-Exchange Programs - Substance Abuse, IntravenousLocation: San Francisco, CA

A Randomized, Controlled Trial of Fluvastatin Added to Pegylated Interferon and Ribavirin (PI+R) Versus PI+R Alone for Treatment of Chronic Hepatitis C Not Previously Treated - NCT00487318-73104
Conditions: Chronic Hepatitis CLocation: OKlahoma City, OK

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-19141
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Philadelphia, PA

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20010
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Washington, DC

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20707
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Laurel, MD

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-23602
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Newport News, VA

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-30060
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Mareitta, GA

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-32803
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Orlando, FL

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-33319
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Tamarac, FL

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-34243
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Sarasota, FL

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-75246
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Dallas, TX

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92105
Conditions: Chronic Hepatitis C Virus Genotype 1Location: San Diego, CA

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92118
Conditions: Chronic Hepatitis C Virus Genotype 1Location: Coronado, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-02114
Conditions: Hepatitis C, ChronicLocation: Boston, MA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-07601
Conditions: Hepatitis C, ChronicLocation: Hackensack, NJ

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-08234
Conditions: Hepatitis C, ChronicLocation: Egg Harbour Township, NJ

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-10016
Conditions: Hepatitis C, ChronicLocation: New York, NY

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-13210
Conditions: Hepatitis C, ChronicLocation: Syracuse, NY

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22031
Conditions: Hepatitis C, ChronicLocation: Fairfax, VA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22908
Conditions: Hepatitis C, ChronicLocation: Charlottesville, VA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-23249
Conditions: Hepatitis C, ChronicLocation: Richmond, VA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27103
Conditions: Hepatitis C, ChronicLocation: Winston-salem, NC

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27599
Conditions: Hepatitis C, ChronicLocation: Chapel Hill, NC

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-28801
Conditions: Hepatitis C, ChronicLocation: Asheville, NC

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30060
Conditions: Hepatitis C, ChronicLocation: Marietta, GA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30308
Conditions: Hepatitis C, ChronicLocation: Atlanta, GA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32256
Conditions: Hepatitis C, ChronicLocation: Jacksonville, FL

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32803
Conditions: Hepatitis C, ChronicLocation: Orlando, FL

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-35294
Conditions: Hepatitis C, ChronicLocation: Birmingham, AL

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-37660
Conditions: Hepatitis C, ChronicLocation: Kingsport, TN

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-38801
Conditions: Hepatitis C, ChronicLocation: Tupelo, MS

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63104
Conditions: Hepatitis C, ChronicLocation: St Louis, MO

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63110
Conditions: Hepatitis C, ChronicLocation: St Louis, MO

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70520
Conditions: Hepatitis C, ChronicLocation: Opelousas, LA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70890
Conditions: Hepatitis C, ChronicLocation: Baton Rouge, LA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-73112
Conditions: Hepatitis C, ChronicLocation: Oklahoma City, OK

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-78234
Conditions: Hepatitis C, ChronicLocation: Fort Sam Houston, TX

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-80045
Conditions: Hepatitis C, ChronicLocation: Aurora, CO

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-84132
Conditions: Hepatitis C, ChronicLocation: Salt Lake City, UT

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-87131
Conditions: Hepatitis C, ChronicLocation: Albuquerque, NM

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90048
Conditions: Hepatitis C, ChronicLocation: Los Angeles, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90057
Conditions: Hepatitis C, ChronicLocation: Los Angeles, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90505
Conditions: Hepatitis C, ChronicLocation: Torrance, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90822
Conditions: Hepatitis C, ChronicLocation: Long Beach, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92037
Conditions: Hepatitis C, ChronicLocation: La Jolla, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92103
Conditions: Hepatitis C, ChronicLocation: San Diego, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-93534
Conditions: Hepatitis C, ChronicLocation: Lancaster, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95816
Conditions: Hepatitis C, ChronicLocation: Sacramento, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95817
Conditions: Hepatitis C, ChronicLocation: Sacramento, CA

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-96813
Conditions: Hepatitis C, ChronicLocation: Honolulu, HI

A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-97239
Conditions: Hepatitis C, ChronicLocation: Portland, OR

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-02905
Conditions: Hepatitis C, ChronicLocation: Providence, RI

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-10021
Conditions: Hepatitis C, ChronicLocation: New York, NY

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-10468
Conditions: Hepatitis C, ChronicLocation: Bronx, NY

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-11030
Conditions: Hepatitis C, ChronicLocation: Manhasset, NY

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-21093
Conditions: Hepatitis C, ChronicLocation: Lutherville, MD

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-23602
Conditions: Hepatitis C, ChronicLocation: Newport News, VA

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-27599
Conditions: Hepatitis C, ChronicLocation: Chapel Hill, NC

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-28304
Conditions: Hepatitis C, ChronicLocation: Fayetteville, NC

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-30033
Conditions: Hepatitis C, ChronicLocation: Decatur, GA

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-32804
Conditions: Hepatitis C, ChronicLocation: Orlando, FL

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-32809
Conditions: Hepatitis C, ChronicLocation: Orlando, FL

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-33143
Conditions: Hepatitis C, ChronicLocation: South Miami, FL

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-37211
Conditions: Hepatitis C, ChronicLocation: Nashville, TN

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-48202
Conditions: Hepatitis C, ChronicLocation: Detroit, MI

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-60637
Conditions: Hepatitis C, ChronicLocation: Chicago, IL

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-70112
Conditions: Hepatitis C, ChronicLocation: New Orleans, LA

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-77030
Conditions: Hepatitis C, ChronicLocation: Houston, TX

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-78215
Conditions: Hepatitis C, ChronicLocation: San Antonio, TX

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-78234
Conditions: Hepatitis C, ChronicLocation: Fort Sam Houston, TX

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-80045
Conditions: Hepatitis C, ChronicLocation: Aurora, CO

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92037
Conditions: Hepatitis C, ChronicLocation: La Jolla, CA

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92123
Conditions: Hepatitis C, ChronicLocation: San Diego, CA

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92154
Conditions: Hepatitis C, ChronicLocation: San Diego, CA

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-94143
Conditions: Hepatitis C, ChronicLocation: San Francisco, CA

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-95817
Conditions: Hepatitis C, ChronicLocation: Sacramento, CA

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-96817
Conditions: Hepatitis C, ChronicLocation: Honolulu, HI

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-97504
Conditions: Hepatitis C, ChronicLocation: Medford, OR

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both - NCT00962871-94143
Conditions: Hepatitis B, ChronicLocation: San Francisco, CA

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02115
Conditions: Hepatitis B, ChronicLocation: Boston, MA

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02903
Conditions: Hepatitis B, ChronicLocation: Providence, RI

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-06106
Conditions: Hepatitis B, ChronicLocation: Hartford, CT

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-10029
Conditions: Hepatitis B, ChronicLocation: New York, NY

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-19104
Conditions: Hepatitis B, ChronicLocation: Philadelphia, PA

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-21287
Conditions: Hepatitis B, ChronicLocation: Baltimore, MD

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-32610
Conditions: Hepatitis B, ChronicLocation: Gainesville, FL

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-75390
Conditions: Hepatitis B, ChronicLocation: Dallas, TX

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-94143
Conditions: Hepatitis B, ChronicLocation: San Francisco, CA

A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, HumanLocation: Baltimore, MD

A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-20892
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, HumanLocation: Bethesda, MD

A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-21205
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, HumanLocation: Baltimore, MD

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-02905
Conditions: Hepatitis C, ChronicLocation: Providence, RI

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-10021
Conditions: Hepatitis C, ChronicLocation: New York, NY

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-11030
Conditions: Hepatitis C, ChronicLocation: Manhasset, NY

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-21093
Conditions: Hepatitis C, ChronicLocation: Lutherville, MD

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-23249
Conditions: Hepatitis C, ChronicLocation: Richmond, VA

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-27599
Conditions: Hepatitis C, ChronicLocation: Chapel Hill, NC

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-37211
Conditions: Hepatitis C, ChronicLocation: Nashville, TN

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-78215
Conditions: Hepatitis C, ChronicLocation: San Antonio, TX

No comments:

Post a Comment